Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis
- 8 February 2019
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 33 (5) , 1268-1272
Abstract
It is well known that staging of patients with AL amyloidosis at diagnosis predicts for survival, but there is a paucity of literature delineating the prognostic value of these systems at relapse. We evaluated the prognostic value of AL staging among 413 patients initiated with second-line therapy between 2000 and 2015. Both the Revised Mayo 2012 and the European revision of Mayo 2004 staging systems were used. The median time from initial treatment to second-line therapy was 11.7 months. The first-line therapy was autologous stem cell transplant (ASCT) in 179 (43%) patients and non-ASCT therapies in 234 patients. Median survival from the institution of second-line therapy was 61 months. Both the Mayo 2004 and 2012 staging systems were of prognostic benefit at second-line therapy with respective risk ratios of 2.78 (95% CI: 2.15, 3.58) and 3.03 (95% CI: 2.33, 3.93) for patients with > stage 2 disease. On multivariate analysis, the predictive value of staging at second-line therapy was independent of stage at diagnosis and prior ASCT as first-line therapy. This study indicates that the Mayo staging systems work well at second-line therapy. Consequently, it is suitable for the stratification of patients in trials for relapsed, refractory AL amyloidosis.Keywords
This publication has 19 references indexed in Scilit:
- Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatmentAmerican Journal of Hematology, 2018
- Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathBlood, 2017
- Immunoglobulin Light Chain Systemic Amyloidosis2016
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosisAmerican Journal of Hematology, 2014
- A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosisBlood, 2014
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisBlood, 2012
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialBlood, 2012
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain MeasurementsJournal of Clinical Oncology, 2012
- Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationBlood, 2006
- Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic AmyloidosisJournal of Clinical Oncology, 2004